carbostyril has been researched along with Brain Neoplasms in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, C; Jiang, Y; Sang, H; Wan, S; Wu, X; Yang, Z; Zhang, J; Zhang, L; Zhang, T; Zhang, X; Zhou, M | 1 |
| Abrey, LE; Aldape, K; Chang, S; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Ebiana, VA; Gilbert, M; Kuhn, J; Levin, VA; Lieberman, F; Mehta, MP; Nghiemphu, PL; Prados, M; Robins, HI; Wen, P; Wright, JJ; Yung, WKA | 1 |
| Brand, C; de Souza, PD; Donabedian, PL; Higgins, GS; Mason, C; Pirovano, G; Reiner, T; Roberts, S | 1 |
| Ahluwalia, MS; Elson, P; Hobbs, BP; McCrae, K; Nixon, AB; Peereboom, DM; Schilero, C; Sharma, M; Stevens, GHJ | 1 |
| Benouaich-Amiel, A; Cohen-Jonathan Moyal, E; De Porre, P; Delisle, MB; Ducassou, A; Favre, G; Filleron, T; Ken, S; Laprie, A; Lubrano, V; Poublanc, M; Sol, JC; Toulas, C; Uro-Coste, E; Verrelle, P | 1 |
| Berry, I; Catalaa, I; Celsis, P; Cohen-Jonathan Moyal, E; Deviers, A; Filleron, T; Ken, S; Laprie, A; Laruelo, A; Lubrano, V; Mogicato, G; Rowland, B | 1 |
| Berry, I; Catalaa, I; Celsis, P; Deviers, A; Filleron, T; Ken, S; Khalifa, J; Laprie, A; Lotterie, JA; Lubrano, V; Moyal, EC; Péran, P | 1 |
| Coch, C; Fimmers, R; Fuhrmann, C; Gielen, GH; Glas, M; Herrlinger, U; Kebir, S; Mack, F; Niessen, M; Reinartz, R; Schäfer, N; Schaub, C; Scheffler, B; Simon, M; Till, A; Tzaridis, T; Wieland, A | 1 |
| Desideri, S; Fisher, J; Grossman, S; Lesser, G; Lustig, R; Mikkelsen, T; Wright, J; Ye, X | 1 |
| Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY | 1 |
| Abrey, L; Chang, S; Cloughesy, TF; DeAngelis, L; Fink, K; Groves, M; Junck, L; Kuhn, J; Lamborn, K; Lieberman, FS; Mehta, M; Paquette, S; Prados, M; Robins, HI; Schiff, D; Sebti, SM; Wen, P; Wright, J; Yung, A | 1 |
| Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; DeAngelis, LM; Fink, KL; Gilbert, MR; Groves, MD; Junck, L; Kuhn, J; Lamborn, KR; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Schiff, D; Wen, PY; Wright, J; Yung, WK | 1 |
| Alaux, B; Berchery, D; Bousquet, P; Catalaa, I; Dalenc, F; De Porre, P; Delannes, M; Laprie, A; Moyal, EC; Poublanc, M; Sabatier, J; Toulas, C | 1 |
| Cohen, K; Fouladi, M; Helton, KJ; Holmes, E; Laningham, F; Nicholson, HS; Pollack, IF; Speights, RA; Wright, J; Zhou, T | 1 |
| Mori, H; Moriwaki, H; Okuno, M; Sugie, S; Suzui, M; Tanaka, T | 1 |
12 trial(s) available for carbostyril and Brain Neoplasms
| Article | Year |
|---|---|
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Sorafenib; Treatment Outcome | 2018 |
Phase II study of Dovitinib in recurrent glioblastoma.
Topics: Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quinolones; Survival Rate | 2019 |
αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fibroblast Growth Factor 2; Focal Adhesion Kinase 1; Glioblastoma; Humans; Integrin alphaVbeta3; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinolones; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vitronectin; Treatment Outcome | 2013 |
Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Choline; Creatine; Female; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Radiotherapy, Conformal; Sensitivity and Specificity | 2014 |
Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cerebrovascular Circulation; Contrast Media; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Quinolones; Radiotherapy; Survival Analysis; Treatment Outcome | 2015 |
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; Female; Glioblastoma; Humans; Male; Microtubule-Associated Proteins; Middle Aged; Quinolones; Receptor, Fibroblast Growth Factor, Type 3 | 2016 |
Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Neurosurgical Procedures; Quinolones; Radiotherapy | 2008 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Quinolones; Temozolomide | 2011 |
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinolones; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Induction; Epilepsy; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Quinolones; Treatment Outcome | 2006 |
Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal | 2007 |
A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Male; Medulloblastoma; Neuroectodermal Tumors; Quinolones; Treatment Outcome | 2007 |
3 other study(ies) available for carbostyril and Brain Neoplasms
| Article | Year |
|---|---|
Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Imidazoles; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Quinolones; src-Family Kinases; Structure-Activity Relationship | 2021 |
[
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Half-Life; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinolones; Radiopharmaceuticals; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2019 |
Different mutation status of the beta-catenin gene in carcinogen-induced colon, brain, and oral tumors in rats.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anthraquinones; beta Catenin; Brain Neoplasms; Carcinogens; Colonic Neoplasms; Cytoskeletal Proteins; Genetic Markers; Male; Methylazoxymethanol Acetate; Mouth Neoplasms; Mutation; Nitrosourea Compounds; Organ Specificity; Polymerase Chain Reaction; Quinolones; Rats; Rats, Inbred F344; Trans-Activators | 2001 |